The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
619
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Thursday, August 2, 2012 : 8:30 AM to 10:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305869 |
|
Title:
|
Biological Optimum Dose-Finding Trials for Cancer Targeted Agents
|
|
Author(s):
|
Hao Liu*+
|
|
Companies:
|
Baylor College of Medicine
|
|
Address:
|
Division of Biostatistics, Houston, TX, 77030, United States
|
|
Keywords:
|
Early phase trial ;
Targeted therapy ;
Bayesian adaptive design ;
Cancer studies
|
|
Abstract:
|
Biological targeted agents can generate optimal treatment effect at a level well below the maximum tolerated dose. Toxicity-guided dose selection designs thus may not work for the purpose of finding the biologically optimal dose level. In this article, we propose a Bayesian adaptive design for dose-finding trials guided by biological responses that directly measure the targeted effect of the study agent. A subject will receive the treatment at the dose level that has the best chance for improving biological response, provided that the dose level has limited toxicity. In addition, a Bayesian rule is incorporated to stop a trial early based on the predictive probability of adverse events. Simulation studies show that the method performed reasonable well. We illustrate the method using an example of a dose-finding trial in advanced renal cell carcinoma.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.